ArticleBMC endocrine disorders2025
Neonatal graves' disease complicated with cholestatic jaundice: a case report.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal cholestatic jaundice and elevated liver enzymes can result from various etiologies, including anatomical, infectious, endocrine, and metabolic abnormalities. Unlike hypothyroidism, hyperthyroidism is rarely associated with neonatal cholestasis. This study presents a unique case of neonatal Graves' disease complicated by cholestatic jaundice and discusses the challenges in diagnosis, treatment, and management. CASE PRESENTATION: We report a 30-day-old male infant, born by vaginal delivery at 36.4 weeks gestational age, born weight was 2550 g, to a mother with a history of hypothyroidism during pregnancy, undiagnosed thyroid disease before. The infant developed manifestations of hyperthyroidism, poor weight gain, and cholestatic jaundice shortly after his inception. A variety of tests were used to confirm the diagnosis of neonatal Graves' disease. After 6 weeks of propylthiouracil and hepatoprotective choleretic therapy, thyroid-thyrotropic hormonal metabolism returned to normal, cholestatic jaundice disappeared after 2 months, and liver enzymes returned to normal after 3 months. In addition, the child's weight and length growth returned to the normal range during the follow-up period.
conclusionsNeonatal Graves' disease can be associated with cholestatic jaundice and may have long-term health consequences for the newborn. Early diagnosis and appropriate treatment are crucial for improving the prognosis. This case emphasizes the importance of monitoring pregnant women for thyroid dysfunction and its potential impact on the newborn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.